Pharmaceutical Executive Daily highlights Pfizer's defense of vaccine data integrity, insights on GLP-1 investments, and ...

Enlaza Therapeutics partners with Vertex Pharmaceuticals to advance innovative therapies for autoimmune diseases using ...

Argo Biopharmaceuticals partners with Novartis to advance innovative siRNA therapies for cardiovascular diseases, enhancing ...

Lily and Novo Nordisk are investing in next-gen GLP-1 drugs and other areas, driven by patent cliffs and venture capital ...

Diagnostics 2.0 is a focus on developing evidence very early on.

As the President points out in his post, the COVID vaccines were developed as part of Project Warp Speed (PWS), an initiative launched by President Trump during his first term. While members of his ...

OMass Therapeutics partners with Genentech to advance innovative treatments for inflammatory bowel disease, leveraging their ...

FDA approves Leqembi Iqlik as a weekly subcutaneous injection for Alzheimer's treatment, enhancing patient convenience and ...

Access Infinity launched a new AI-powered price and health technology assessments (HTA) for its market access insights ...

Wayrilz is the first Bruton’s tyrosine kinase inhibitor to be approved for adults with persistent or chronic immune ...

Eli Lilly's oral GLP-1 receptor agonist Orforglipron showed significant weight loss, A1C reduction, and cardiometabolic ...

PE: Is collecting RWD more complicated in today’s world? Nasser: Techniques like data federation start to reduce the burden and activation energy of collecting data. If we were trying to centralize ...